Many voices are chiming in during the countdown to oral arguments in a high profile Supreme Court biosimilar case being watched by biopharmaceutical industry stakeholders.
The Supreme Court is receiving briefs from the parties and friends of the court in Amgen v. Sandoz, a case in which the high court is expected to clarify how and when biosimilars may be approved and sold in the U.S. The court will hear oral arguments in this case April 26—Bloomberg BNA will be there—and a decision is expected in June.
The court is reviewing a decision by the U.S. Court of Appeals for the Federal Circuit interpreting the Biologic Price Competition and Innovation Act (BPCIA). The statute creates an abbreviated approval pathway for biosimilars—highly similar versions of FDA-approved biologics. The biosimilars are expected to be priced 15 percent to 30 percent less than the original biologic. Considering some biologics cost $80,000 a year or more, that’s a lot of money saved.
The statute includes provisions for the biosimilar applicant and the owner of the biologic patent to exchange information to facilitate the decision by the patent owner as to whether or not the biosimilar is infringing its patent. The parties have different interpretations of the statute, and Sandoz has told the Supreme Court that one result of the Federal Circuit’s ruling is that all biosimilars will be delayed from going on the market for six months.
On the road to the Supreme Court’s decision in June, nine friends of the court briefs were submitted to the court in support of Sandoz’s position, including one by the U.S. government. To date, five briefs have been submitted in support of Amgen, which argues that the statute has a mechanism to protect the rights of the patent holders for the original biologics and that Sandoz’s position will weaken that mechanism.
One of the briefs came from AbbVie Inc., which is in a unique position to comment on the dispute. Like Amgen, it is the owner of an original biologic for which a biosimilar has been approved by the FDA. AbbVie owns the patents covering Humira (adalimumab), which treats rheumatoid arthritis, psoriasis and Crohn’s Disease. AbbVie also is suing Amgen, the maker of Amjevita, a biosimilar of AbbVie’s Humira, contending the Amgen biosimilar infringes its patents. I wrote about AbbVie’s brief and the story is here.
On other fronts, stakeholders have been talking about the law as currently interpreted by the Federal Circuit and as administered by the FDA. I covered a panel discussion in which an attorney who had worked for the FDA suggested that resolution of biosimilar regulation issues hasn’t been as slow as people think. That article is here.
Suffice it to say, a lot is happening in the white hot biosimilar area, and Bloomberg BNA will continue to keep you abreast of all of the most important developments.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)